Dimerix DXB.AX · AUD

Its shares trade on ASX under the ticker DXB.AX. It has been listed since 5 July 1989. In the fiscal year to 30 June 2026, it reported revenue of A$4.4m and a net loss of A$29.8m. At that date it held total assets of A$58.6m and shareholders' equity of −A$14.8m.

Dimerix Ltd. is a clinical stage biopharmaceutical company, which engages in the development of new therapeutic treatments identified using its proprietary drug discovery platform, Receptor-Heteromer Investigation Technology. The company is headquartered in Melbourne, Victoria. The firm's principal activity is the development of its DMX-200 clinical asset for the treatment of chronic kidney disease and the commercialization of its underlying drug discovery technology. The firm's business segments are the development of occupational drug testing devices and new therapeutic agents in Australia, and clinical-stage drug discovery and development in Australia. Its DMX-200 is a combination of two existing drugs: irbesartan and propagermanium. DMX-200 is in Phase II clinical trials. The company also has additional programs in its pipeline, including therapeutic candidates for treatment of Nonalcoholic Steatohepatitis (NASH) (fatty liver disease), Ocular diseases, Cancer fatigue and Multiple sclerosis.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Mark DiamondNon-Executive Chairman of the Board
• Dr. Nina WebsterChief Executive Officer, Managing Director, Director, since 2018A$407,849
• Mr. Hamish GeorgeChief Financial Officer, Company Secretary
• Dr. David FullerChief Medical Officer
• Dr. Ash SomanMember of the Executive Board
• Mr. Hugh AlsopNon-Executive DirectorA$60,000
• Dr. Sonia PoliNon-Executive DirectorA$60,000
• Mr. Clinton SnowNon-Executive Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.